SEC Form 4 · accession 0001179110-17-006686
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean-Pierre Bizzari
Director
Period of report
May 4, 2017
Accepted (ET)
May 5, 2017 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2017 | A | 14,135 | $0.00 | A | 50,949 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 4, 2018 and (ii) the date of the Issuer's next annual meeting of stockholders.